To describe factors associated with survival in human immunodeficiency virus (HIV)-infected subjects with non-small cell lung cancer (NSCLC) and analyze toxicities induced by cytotoxic chemotherapy and antiretroviral compounds. Design: Retrospective analyses of HIV-infected subjects with NSCLC enrolled in the Dat'Aids cohort. A toxicity substudy included subjects treated by at least one cycle of cytotoxic chemotherapy. Methods: Survival was analyzed using Cox models. In the toxicity substudy, factors associated with grade 4 hematological toxicity of each episode of combination of antiretroviral drugs and cytotoxic chemotherapy were analyzed using marginal logistic regression models. Results: Fifty-two subjects were included in the study: 42 were men, median age was 48 years, 98% were smokers, with a median of 30 pack years, median CD4 was 300 cells/l, and median survival time was 12 months. CD4 levels Ն200 cells/l at NSCLC diagnosis (hazard ratio [HR] ϭ 0.29, 95% confidence interval [CI] [0.10 -0.89]), performance status less than 2 (HR ϭ 0.32, 95% CI [0.15-0.68]) and highly active antiretroviral therapy (HR ϭ 0.26, 95% CI [0.09 -0.74]) were significantly associated with increased survival in the multivariable model. Forty subjects were included in the toxicity substudy, and 14 among 68 different combinations were complicated by a grade 4 hematological toxicity. Protease inhibitor use (odds ratio ϭ 5.22, 95% CI [1. 07-25.38]) was significantly associated with grade 4 hematological toxicity in the multivariable analyses. Conclusions: In HIV-infected patients, CD4 levels at NSCLC diagnosis may be a predictive factor of survival. Use of highly active antiretroviral therapy during NSCLC chemotherapy is warranted, but protease inhibitors should be used with caution, as they may enhance severe hematological toxicities.
D espite highly active antiretroviral therapy (HAART), the incidence of some non-acquired immunodeficiency syndrome (AIDS) cancers in human immunodeficiency virus (HIV)-infected subjects is significantly increased compared with non-HIV-infected subjects in resource-rich settings. 1, 2 Among these cancers, lung cancer is the primary cause of mortality by non-AIDS cancers in the HIV-infected population 1,3-7 even after adjusting for age, sex, 1, 3, 7 and smoking history. 5, 8 HIV-related immunodeficiency may explain in part the increased risk of lung cancer in the HIV-infected population, 2, 5, 8, 9 although smoking remains the primary risk factor.
There are no specific recommendations for the management of lung cancers in the HIV-infected population. In the general population, patients with advanced non-small cell lung cancer (NSCLC) are usually treated with a combination of a platinum drug (cisplatin or carboplatin) and a third generation nonplatinum drug (docetaxel, gemcitabine, irinotecan, paclitaxel, pemetrexed, or vinorelbine) resulting in a slight increase in survival and relief of cancer-related symptoms. 10 Strategies aiming to further improve survival of patients with advanced NSCLC include the addition of targeted drugs to cytotoxic chemotherapy, such as epidermal growth factor receptor or antivascular endothelial growth factor monoclonal antibodies, 11, 12 receptor protein kinase inhibitors, 13 and pursuing maintenance therapy with pemetrexed after first-line chemotherapy. 14 The aim of antiretro-viral treatment is to provide durable virological, immunological, and clinical benefits, while minimizing toxicities and drug resistance. Two Nucleos(t)ide Reverse Transcriptase (NRTI) (usually tenofovir or abacavir ϩ emtricitabine or lamivudine) plus either an Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) (usually efavirenz) or a protease inhibitor (PI) with ritonavir are the most common initial therapies. 15 Raltegravir, an integrase inhibitor, maraviroc, a CCR5 coreceptor inhibitor inhibiting HIV entry, and etravirine, a second generation NNRTI, and the fusion inhibitor enfuvirtide have potent antiretroviral inhibition provided they are associated with at least one and at best two fully active agents and are usually prescribed in drug-experienced HIVinfected subjects.
When managing NSCLC in HIV-infected subjects, PIs with or without ritonavir may modify concentrations of antineoplastic compounds through CYP450 inhibition, potentially intensifying cytotoxic therapy adverse events. 16 Some antiretroviral compounds, such as zidovudine (ZDV), could also be responsible for additive hematological toxicities with antineoplastic drugs. Studies providing a detailed analysis of factors involved in survival and adverse events with a combination of HAART and cytotoxic chemotherapy are scarce in HIV-infected subjects. Case reports and case series of potentially lethal interactions between PI and chemotherapy in Hodgkin lymphomas, 16 -19 Castelmann disease, 20 or non-Hodgkin lymphoma 21, 22 have been published, but data, particularly concerning non-AIDS defining cancers, including NSCLC, are lacking.
The objective of our study was to describe factors associated with increased survival rates in HIV-infected subjects with NSCLC in a French cohort, the Dat'Aids cohort. 23 A substudy analyzed the occurrence of toxicities induced by cytotoxic chemotherapy (the toxicity substudy) and their association with specific antiretroviral classes and compounds.
PATIENTS AND METHODS

Collection of Patient Data
Patients were included in the study if they were HIV infected, followed in the Dat'Aids cohort and had a histological diagnosis of NSCLC. The database was frozen on November 30, 2009. To allow a sufficient follow-up, we included only patients with a diagnosis of NSCLC before November 30, 2008. All the patients who were treated with Ն1 chemotherapeutic administration were included in a toxicity substudy. Administration of HAART with chemotherapy was not mandatory for inclusion in the study.
Dat'Aids is a cohort derived from NADIS, an electronic medical record for HIV-infected patients seeking care in French public hospitals. Patients' data are recorded with no time delay in a structured database, allowing use for clinical, epidemiological, or therapeutic studies. 23 Between January 1996 and November 30, 2009, 20,874 subjects had their data recorded at least once in the base. All patients are included in the NADIS medical record after receiving oral information and giving written consent. The collected data and details of the networking organization have been submitted to the French National Commission on Informatics and rights. All patients' medical records included in the study were retrospectively reviewed by two of the authors (A.M. and J.-C.T.) in each center and unit implicated in the caring of patients.
Statistical Analysis
The primary objective was to determine factors associated with survival after NSCLC diagnosis using Cox proportional hazards models. Survival was defined by the absence of death from any cause. Variables studied were gender, age, CD4 level at NSCLC diagnosis, nadir CD4 level, a history of AIDS according to the 1993 CDC classification, viral load at diagnosis, diagnosis of adenocarcinoma or not, performance status (PS) at NSCLC diagnosis, NSCLC staging, and treatment with chemotherapy and antiretroviral therapy. NSCLC stages were reclassified according to the proposals for the revision of the tumor, node, and metastasis stage groupings in the forthcoming (seventh) edition of the Tumor, Node, and Metastasis Classification of Malignant Tumors of the IASLC Lung Cancer Staging Project. 24, 25 Patients with stages I to II were pooled together, as were patients with stages IIIA and IIIB, to increase statistical power. The multivariable Cox model included all potential prognostic factors for survival with a p value less than 0.2 in univariate analysis.
For the toxicity substudy, as patients could have changed antiretroviral or cytotoxic therapy during their follow-up, we defined a therapeutic combination as the specific association of a defined HAART and chemotherapy type. Modification of a therapeutic combination was defined as either the changing of at least one of the cytotoxic compounds (e.g., docetaxel to pemetrexed) or a switch of one of the antiretroviral compounds from one antiretroviral class to another (e.g., PI to integrase inhibitor) or the introduction or interruption of ZDV in the backbone. The outcome variable was the presence of grade 4 hematological toxicity according to the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS) clinical trial adverse event classification, defined as a grade 4 neutropenia (Ͻ500 cells/mm 3 ), a grade 4 anemia (hemoglobin level Ͻ6.5 g/dl), or a grade 4 thrombocytopenia (Ͻ20,000 platelets/mm 3 ). Marginal logistic regression models, which account for correlation between observations, were used to identify factors associated with grade 4 hematological toxicity. The correlation of observations within each patient was modeled assuming exchangeable correlation for the working correlation matrix, and the variance was estimated by the sandwich estimator. In addition to all the variables listed for survival analysis, uses of PI or ZDV in HAART and first versus two or more chemotherapy lines were also studied. Variables with a p value less than 0.2 in the univariate approach were included in the multivariable model.
All analyses were performed using Stata 10.1 (Stata Corp, College Station, TX), and statistical significance was set at 0.05. these, 42 were treated with cytotoxic chemotherapy, but two subjects were excluded from the toxicity substudy as chemotherapeutic tolerance data were not available.
Baseline Characteristics and Patient Description
Of the 52 included subjects in the study, 42 were men (81%), median age at NSCLC diagnosis was 48 years, 98% had been or were active smokers (median of 30 pack years), median CD4 was 300 cells/l, and 38 (73%) had a CD4 cells Ն200/L at NSCLC diagnosis (Table 1 ). Median follow-up time was 12 months (range: 0.6 -83 months), and median survival was 12 months.
Forty subjects were included in the toxicity substudy. Characteristics were comparable with the main study, except for the number of subjects with a nadir level of CD4 Ն200 cells/l ( Table 1) . Patients received from one to five therapeutic combinations and overall 68 therapeutic combinations were administered: 24 with docetaxel, 16 with gemcitabine, and 12 with vinorelbine. The remaining combinations contained pemetrexed (n ϭ 2), etoposide (n ϭ 2), erlotinib (n ϭ 5), and gefitinib (n ϭ 2). Forty-five combinations were platin-based doublets, and two had platinium-based triplets. One subject received cisplatin monotherapy. Fourteen combinations included ZDV, 21 were NNRTI based, and 20 were PI based (seven were ritonavir boosted, four also included a NNRTI, and one raltegravir). Other HAART included raltegravir ϩ NRTI (n ϭ 4) and Ն3 NRTIs (n ϭ 8). Fifteen combinations did not include any antiretroviral therapy.
Factors Associated with Survival
Results of the Cox models assessing factors associated with survival in the 52 HIV-infected subjects with NSCLC are listed in Table 2 . Variables included in the multivariable model were a CD4 level Ն200 cells/l at NSCLC diagnosis, a PS less than 2, NSCLC stages, use of chemotherapy, and use of HAART after lung cancer diagnosis. The characteristics significantly associated with increased survival in the multivariable model were CD4 levels Ն200 cells/l at NSCLC diagnosis (hazard ratio [HR] ϭ 0.29, 95% confidence interval [CI] [0.10 -0.89]), a PS less than 2 (HR ϭ 0.32, 95% CI [0.15-0.68]), and use of HAART after NSCLC diagnosis (HR ϭ 0.26, 95% CI [0.09 -0.74]). There was a trend to an increased survival with use of cytotoxic chemotherapy in the unadjusted Cox model, but this element was no longer statistically associated with increased survival (HR: 0.95, 95% CI [0.34 -3.31]) after adjustment for other prognostic factors. Stages I to II or III versus stage IV at lung cancer diagnosis was not significantly associated with overall survival in multivariate analysis, although there was a tendency for stages I to II versus IV (HR ϭ 0.24, 95% CI [0.05-1.20], p ϭ 0.08). Figure 1 assembles Kaplan-Meier survival estimates according to HAART pursuit after NSCLC diagnosis, CD4 level at NSCLC diagnosis, and PS.
Factors Associated with Grade 4 Toxicity
Overall, 14 of 68 therapeutic combinations were complicated by a grade 4 hematological toxicity in 13 patients. Characteristics and outcomes of the 14 combinations induc-ing grade 4 hematological toxicity are summarized in Table  3 . Nine of these combinations included a CYP-metabolized agents (docetaxel n ϭ 3, vinorelbine n ϭ 5, and etoposide n ϭ 1), of which seven had a PI coadministered. In contrast, only one induced grade 4 hematological toxicity occurred in a combination with an NNRTI. Among the 13 combinations including ZDV, five combinations induced grade 4 toxicity. Ten combinations resulted in grade 4 neutropenia, and all six deaths due to hematological toxicity were secondary to septic shock occurring during a grade 4 neutropenia. Five of these six deaths occurred under combinations with a PI, of which four also included a CYP-metabolized cytotoxic compound.
Variables associated with grade 4 hematological toxicity using marginal logistic regression models are listed in 
DISCUSSION
This study included subjects from a French National Database of HIV-infected patients (the Dat'Aids cohort) with NSCLC. We found that a PS less than 2, a CD4 count Ն200 cells/l at NSCLC diagnosis, and use of HAART after NSCLC diagnosis were significantly associated with increased survival in the multivariable model. We also found that the use of a PI-containing antiretroviral regimen with cytotoxic chemotherapy was independently associated with at least one episode of hematological grade 4 toxicity. Death due to hematological toxicity was mostly observed in patients receiving a PI.
In comparison with NSCLC in the general population, NSCLC in HIV-infected patients is characterized by young age at diagnosis and an increased proportion of advanced stages III and IV at diagnosis. 26 -28 Nearly all HIV-infected subjects with NSCLC are smokers. Histological subtypes in the HIV-infected population follow the patterns of histological subtypes in the general population, with a predominance of adenocarcinoma (31-52%) followed by carcinoid epidermoid (17-50%) and other histological subtypes. 5, [27] [28] [29] The subjects included in our study compared well with the retrospective studies of NSCLC of the HIV-infected population in regards to the patients' baseline characteristics, advanced stages of discovery, and dismal prognosis: median age was 48 years, 71% had adenocarcinoma, 27% squamous carcinoma, nearly all were smokers, 90% had their NSCLC discovered at advanced stages III or IV, and median survival was 12 months.
The factors associated with increased survival in our study are similar to those of a recent retrospective study of 49 HIV-infected subjects with NSCLC. 26 Lavole et al. also found that PS less than 2 and treatment with HAART were associated with improved survival in multivariate analyses (respectively, HR ϭ 0.2, 95% CI [0.09 -0.46] and HR ϭ 0.4, 95% CI [0.2-0.9]). PS is a well-known prognostic factor in NSCLC and cancers in the general population 30 and has been highlighted as an essential prognostic factor in some cancers in the HIV-infected population. 31 We confirm the importance of PS as a significant survival prognostic factor in NSCLC in the HIV-infected population in our study, as well as the use of HAART, underscoring the necessity of initiating or pursuing HAART after NSCLC diagnosis whenever possible. Whether increased survival with HAART reflects immunemediated control of the tumor needs to be further investigated, but survival seemed to be independent of opportunistic infections in our study, as they did not occur. Other studies have also confirmed enhanced survival and remission rates with a strategy of pursuing HAART with chemotherapy for non-Hodgkin 22,32-36 and Hodgkin lymphomas. 37, 38 We found that the level of CD4 Ն200 cells/l at NSCLC diagnosis was associated with increased survival. Several studies have highlighted the role of HIV-induced immunodeficiency in the occurrence of lung cancer. 8, 9 Guiguet et al. found in 52,278 patients followed up in the French Hospital Database on HIV cohort during 1998 -2006 that the current CD4 cell count was the most predictive risk factor for lung cancer. Compared with patients with CD4 count greater than 500 cells/l rate, ratios ranged from 2.2 (1.3-3.6) to 8.5 (4.3-16.7) for lung cancer for CD4 levels of 350 -499 cells/L and less than 50 cells/l, respectively (p Ͻ 0.0001). The rapid evolution and the high proportions of advanced stage lung cancers at diagnosis in the HIV-infected population, 5, 27, 28 as encountered in our study, also suggest an increased tumor cell proliferation in HIV-infected patients with NSCLC potentially fostered by cellular immunodeficiency. A recent phase II clinical trial in the non-HIVinfected patients with NSCLC showed some survival benefit of cellular vaccination against tumoral cells, underscoring the importance of immunity in controlling the disease. 39 Similar to our study, another retrospective study of 92 HIV-infected patients with NSCLC showed, after adjustment on NSCLC stage at diagnosis, that CD4 counts levels less than 400 cells/l and less than 200 cells/l were significantly associated with increased mortality (respectively, HR: 1.61; 95% CI [0.82-3.16] and HR: 2.64; 95% CI [1.37-5.10]) in comparison with CD4 levels more than 400 cells/l. 28 Our study did not find an independent association between NSCLC stages and survival, a factor commonly associated with increased survival in the general population with NSCLC and in the HIV-infected population. 26 Nevertheless, NSCLC stages I to II had a trend to increased survival in comparison with subjects with stage IV (HR ϭ 0.24; 95% CI [0.05-1.20], p ϭ 0.08). These results could be partially explained by a lack of power in our study, as only five subjects (10%) were classified as stage I or II and 13 (25%) as stage III (A or B) . Also, one patient staged IA and three staged IIIA did not have surgery, and one patient with stage IIIA NSCLC did not have neoadjuvant chemotherapy.
Use of cytotoxic chemotherapy was not associated with overall survival. This result could be explained not only by lack of power of our retrospective study but also because few patients did not receive chemotherapy (Table 1) . Some patients received chemotherapy (such as the well-tolerated gemcitabine monotherapy) as palliative care, solely aimed to relieve symptoms. In the general population with advanced NSCLC, chemotherapy has only shown a moderate increase in survival. A meta-analysis of 16 prospective randomized trials comparing chemotherapy with best supportive care in 2714 subjects with advanced NSCLC showed only a very modest increase in the 1-year survival of 20 to 29%. 40 Increased survival with newer agents targeting tyrosine kinase pathways have shown enhanced survival of gefitinib versus carboplatin-paclitaxel in adenocarcinoma, particularly in East Asian and non or light smokers, 13 and with erlotinib in subjects with the activating mutations in the epidermal growth factor genes. 41 In our study, only seven combinations included gefitinib or erlotinib in second or third-line therapies, and none had epidermal growth factor receptor gene mutation screening or any favorable factor associated with increased survival in NSCLC.
In the toxicity substudy, use of PI was significantly associated in multivariate analyses with more frequent grade 4 hematological toxicity. ZDV use was not significantly associated with grade 4 toxicity, although there was a trend. These results and the detailed description of the 14 combinations that induced these grade 4 toxicities underscore two possible mechanisms of toxicity: the first through CYP450mediated interactions between PI and CYP-metabolized cytotoxic compounds (primarily vinorelbine and docetaxel) and the second through ZDV additive hematological depletion enhanced by cytotoxic compounds. Antineoplastic agents used in NSCLC and metabolized by the CYP450 include taxanes, vinca alkaloids, etoposide, and the anilinoquinazolines erlotinib and gefitinib. 16, [42] [43] [44] All PIs inhibit CYP450 3A4, but ritonavir is the most potent inhibitor in the class, even at low doses. 45, 46 Ritonavir is also a potent inhibitor of the P-glycoprotein efflux pump protein, driving chemotherapeutic drugs, such as vinca alkaloids and taxanes, outside tissues and cells. 47, 48 The frequent occurrence of grade 4 hematological toxicity early in the cycles of most CYP-450mediated chemotherapy and PI administration during the first of chemotherapy lines line supports a toxicity mechanism through drug to drug interaction (Table 3 ). Case reports of life-threatening neutropenia possibly due to CYP-450-mediated interactions have been published between PI inhibitors and taxanes, 49 -51 or vinca alkaloids. 16, 22, 52 In a recent analysis of 16 HIV-infected subjects with Hodgkin lymphoma treated by vinblastine-based chemotherapy, use of PI-containing HAART was significantly associated with grades III to IV World Health Organization neutropenia. 19 ZDV hematological toxicities, including anemia and neutropenia, are wellknown adverse events, 53 and use of ZDV with chemotherapy should be avoided. 54 PS less than 2 was not associated with increased grade 4 hematological toxicity in the multivariable (Table 4 ). This result could be explained by a lack of power in our study, as PS is a well-known prognostic factor of cytotoxic chemotherapy tolerance in lung cancer in the general population. 55 Our study has some methodological shortcomings. First, although the Dat'Aids cohort is a prospective cohort, some data had to be completed retrospectively, particularly those concerning chemotherapies and adverse events. Nevertheless, we believe that the careful study of each patient's medical record resulted in reliable information. Second, our study results were limited by the number of subjects included. We could not analyze, for instance, a potential difference in terms of toxicity of a ritonavir boosted or nonboosted PIcontaining regimens. Nevertheless, although lung cancer is in most cohorts the first non-AIDS defining cancer in HIVinfected subjects, 1,3-7 incidence rates are relatively low, making studies with an important number of subjects difficult to carry out.
In conclusion, our study showed that PS less than 2, HAART during chemotherapy, and a CD4 level Ն200 cells/l at NSCLC diagnosis were associated with increased survival in a HIV-infected population with NSCLC, mostly with advanced NSCLC stages. Subjects with NSCLC stages I to II had a better outcome than subjects with stage IV NSCLC, although this difference was not statistically significant. These results advocate the use of HAART during chemotherapy for NSCLC, and the early implementation of HAART, as severe immunological depression could enhance the risk of NSCLC and nonresponse to antineoplastic chemotherapy. Our study also underscores the importance of installing smoking interruption programs in the HIV-infected population as nearly all HIV-infected subjects with lung cancers are smokers. Our toxicity substudy also suggests that use of non-PI-based HAART may be preferred when cytotoxic chemotherapies metabolized by the CYP450 pathway are administered. The choice of chemotherapy and HAART in HIVinfected patients with NSCLC should be individualized and multidisciplinary and decided in light of the possible interactions and additive toxicities between compounds, while preserving quality of life and viral suppression. Clinical and PK studies of interactions with chemotherapy and antiretroviral drugs are warranted for NSCLC and other cancers in the HIV-infected population, as well as prospective data on survival.
